AR055017A1 - Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos - Google Patents

Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos

Info

Publication number
AR055017A1
AR055017A1 ARP050105493A ARP050105493A AR055017A1 AR 055017 A1 AR055017 A1 AR 055017A1 AR P050105493 A ARP050105493 A AR P050105493A AR P050105493 A ARP050105493 A AR P050105493A AR 055017 A1 AR055017 A1 AR 055017A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
alkylamino
amino
halogen
Prior art date
Application number
ARP050105493A
Other languages
English (en)
Inventor
Ian Alun Nash
Kenneth Mark Page
Paul Allen Bethel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0428326A external-priority patent/GB0428326D0/en
Priority claimed from GB0507513A external-priority patent/GB0507513D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR055017A1 publication Critical patent/AR055017A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos, procesos para su preparacion, composiciones farmacéuticas que los contienen y uso del compuesto para la fabricacion de medicamentos. Estos compuestos son utiles para el tratamiento de enfermedades inflamatorias y alérgicas co o inflamacion del tracto gastrointestinal, enfermedades de la piel, respiratorias, hipertension y enfermedades del metabolismo oseo (como osteoporosis). Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) en donde m es 0, 1 o 2; R1 es halogeno, hidroxi, ciano, trifluorometilo, trifluorometoxi, C1-6 alquilo, C1-6 alcoxi, C2-6 alquenilo, C2-6 alquinilo, C2-6 alcanoílo, C1-6 alquiltio, C1-6 alquilsulfinilo, C1-6 alquilsulfonilo, hidroxi-C2-6 alcoxi, amino C2-6 alcoxi, ciano-C2-6 alcoxi, C1-6 alquilamino-C2-6 alcoxi, di-[C1-6 alquil]amino-C2-6 alcoxi, C1-6 alcoxi-C2-6 alcoxi, carbamoil-C1-6 alcoxi, N-C1-6 alquilcarbamoil-C1-6 alcoxi, amino-C1-6 alquilo, C1-6 alquilamino-C1-6 alquilo, di[C1-6 alquil] amino-C1-6 alquilo, carbamoil-C1-6 alquilo, N-C1-6 alquilcarbamoil-C1-6 alquilo, hidroxi-C2-6 alquilamino, ciano-C2-6 alquilamino, halogeno, C2-6 alquilamino, amino-C2-6 alquilamino, C1-6 alcoxi-C2-6 alquilamino, C1-6 alquilamino-C2-6 alquilamino, di-[C1-6 alquil]amino-C2-6 alquilamino, heteroarilo, heteroaril-C1-6-alquilo, heteroariloxi, heteroaril-C1-6 alcoxi, heteroarilamino, heterociclilo, heterociclil-C1-6 alquilo, heterocicliloxi, heterociclil-C1-6 alcoxi y heterociclilamino, y en donde cualquier grupo arilo, heteroarilo o heterociclilo en un sustituyente R1 puede tener opcionalmente 1 o 2 sustituyentes seleccionados entre hidroxi, halogeno, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C3-6 cicloalquilo, C3-6 cicloalquil-C1-6 alquilo, C3-6 cicloalquil-C1-6 alcoxi, C1-6 alcoxi, carboxi, C1-6 alcoxicarbonilo, C1-6 alcoxicarbonil-C1-6 alquilo, N-C1-6 alquilcarbamoílo, N,N-di-[C1-6 alquil]carbamoílo, C2-6 alcanoílo, amino, C1-6 alquilamino, di-[C1-6 alquil]amino, halogeno-C1- 6 alquilo, hidroxi-C1-6 alquilo, C1-6 alcoxi-C1-6 alquilo, ciano-C1-6 alquilo, carboxi C1-6 alquilo, amino-C1-6 alquilo, C1-6 alquilamino-C1-6 alquilo y di-[C1-6 alquil]amino-C1-6 alquilo, y en donde y cualquiera de los sustituyentes R1 definidos precedentemente que comprende un grupo CH2 que está unido a 2 átomos de C o un grupo CH3 que está unido a un átomo de C o de N puede tener opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes seleccionados entre halogeno, hidroxi, amino, trifluorometilo, trifluorometoxi, oxo, carboxi, carbamoílo, acetamido, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C3-6 cicloalquilo, C3-6 cicloalcoxi, C1-6 alcoxi, C1-6 alquilamino, di-[C1-6 alquil]amino, hidroxi-C1-6 alquilo, C1- 6 alcoxi-C1-6 alquilo, halogeno-C1-6 alquilo, C1-6 alcoxi-C2-6 alcoxi, C1-6 alcoxicarbonilo, carbamoílo, N- C1-6 alquilcarbamoílo, N,N-di-[C1-6 alquil]carbamoílo, C1-6 sulfonilo, C1-6 sulfamoílo, heteroarilo, heteroaril-C1-6 alquilo, heterociclilo y heterocicliloxi, y en donde cualquier grupo heterociclilo en un sustituyente R1 puede tener opcionalmente 1 o 2 sustituyentes oxo o tioxo; R2 es halogeno, trifluorometilo o C1-6 alquilo; R3 es H, halogeno, trifluorometilo, ciano o C1-6 alquilo; R4 es C3-6 cicloalquilo, C1-6 alquilo o heteroarilo, y R4 puede estar opcionalmente sustituido por uno o más sustituyentes seleccionados entre halogeno, hidroxi, amino, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C1-6 alcoxi, C1-6 alquilamino y di- [C1-6 alquil]amino; y R5 es H, halogeno, trifluorometilo, ciano o C1-6 alquilo; o su sal aceptable para uso farmacéutico.
ARP050105493A 2004-12-24 2005-12-22 Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos AR055017A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0428326A GB0428326D0 (en) 2004-12-24 2004-12-24 Amide derivatives
GB0507513A GB0507513D0 (en) 2005-04-14 2005-04-14 Amide derivatives

Publications (1)

Publication Number Publication Date
AR055017A1 true AR055017A1 (es) 2007-08-01

Family

ID=35840517

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105493A AR055017A1 (es) 2004-12-24 2005-12-22 Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos

Country Status (21)

Country Link
US (1) US7786115B2 (es)
EP (1) EP1831174B1 (es)
JP (1) JP4937135B2 (es)
KR (1) KR20070095911A (es)
CN (1) CN102516170A (es)
AR (1) AR055017A1 (es)
AT (1) ATE500227T1 (es)
AU (1) AU2005317868B2 (es)
BR (1) BRPI0519287A2 (es)
CA (1) CA2589764A1 (es)
DE (1) DE602005026703D1 (es)
HK (1) HK1106245A1 (es)
IL (1) IL183657A (es)
MX (1) MX2007007424A (es)
MY (1) MY140868A (es)
NO (1) NO20073730L (es)
NZ (1) NZ555768A (es)
RU (1) RU2396259C2 (es)
TW (1) TWI364415B (es)
UY (1) UY29301A1 (es)
WO (1) WO2006067444A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2929331B2 (ja) * 1990-07-18 1999-08-03 丸善石油化学株式会社 トラクションドライブ用流体
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
GB0504019D0 (en) * 2005-02-26 2005-04-06 Astrazeneca Ab Amide derivatives
GB0516570D0 (en) * 2005-08-12 2005-09-21 Astrazeneca Ab Amide derivatives
CN101506171A (zh) * 2006-06-19 2009-08-12 阿斯利康(瑞典)有限公司 作为细胞因子介导的疾病的抑制剂的异喹啉衍生物及其用途
WO2008024961A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Dihydropyridazine, tetrahydropyridine, chromanone, and dihydronaphthalenone derivatives as heat-shock protein 90 inhibitors
NZ579890A (en) 2007-03-20 2012-05-25 Celgene Corp 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
CL2008000973A1 (es) 2007-04-05 2009-01-02 Astrazeneca Ab Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
WO2009098144A1 (en) * 2008-02-05 2009-08-13 F. Hoffmann-La Roche Ag Novel pyridinones and pyridazinones
PT2105164E (pt) 2008-03-25 2011-03-24 Affectis Pharmaceuticals Ag Novos antagonistas de p2x7r e a sua utilização
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
MX2011010810A (es) 2009-04-14 2012-01-12 Affectis Pharmaceuticals Ag Nuevos antagonistas de p2x7r y su uso.
WO2011010131A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Compositions comprising an oxoisoquinoline methylbenzamide and a polymer
US9309238B2 (en) * 2009-11-05 2016-04-12 University Of Notre Dame Du Lac Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
EP2569281A1 (en) 2010-05-14 2013-03-20 Affectis Pharmaceuticals AG Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP2686303B1 (de) 2011-03-18 2016-01-20 Bayer Intellectual Property GmbH N-(3-carbamoylphenyl)-1h-pyrazol-5-carboxamid- derivate und ihre verwendung zur bekämpfung von tierischen schädlingen
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5136461A (en) * 1974-09-24 1976-03-27 Grelan Pharmaceutical Co 44 * 22 isokarubosuchiririiru * fuenirusakusanruinoseizoho
JPS5143766A (en) * 1974-10-09 1976-04-14 Grelan Pharmaceutical Co 44 * 22 * 3*44 jihidoroisokarubosuchiririiru * * fuenirusakusanruino seizoho
ES2152938T3 (es) * 1992-09-28 2001-02-16 Hoechst Ag 1(2h)-isoquinolinas sustituidas antiarritmicas y cardioprotectoras, procedimiento para su produccion, medicamento que las contiene y su uso para la produccion de un medicamento para combatir fallos cardiacos.
US7008945B1 (en) * 1999-03-17 2006-03-07 Astrazeneca Ab Amide derivatives
JP2002220386A (ja) * 2000-10-02 2002-08-09 Tanabe Seiyaku Co Ltd ベンジルアミン誘導体、その製法およびその合成中間体
GB0504019D0 (en) 2005-02-26 2005-04-06 Astrazeneca Ab Amide derivatives
GB0516570D0 (en) 2005-08-12 2005-09-21 Astrazeneca Ab Amide derivatives

Also Published As

Publication number Publication date
BRPI0519287A2 (pt) 2009-01-06
KR20070095911A (ko) 2007-10-01
TW200635901A (en) 2006-10-16
CN102516170A (zh) 2012-06-27
EP1831174B1 (en) 2011-03-02
NZ555768A (en) 2009-12-24
AU2005317868B2 (en) 2009-06-04
JP4937135B2 (ja) 2012-05-23
UY29301A1 (es) 2006-07-31
MX2007007424A (es) 2007-07-17
WO2006067444A1 (en) 2006-06-29
US20080146566A1 (en) 2008-06-19
RU2007130153A (ru) 2009-02-20
CA2589764A1 (en) 2006-06-29
HK1106245A1 (en) 2008-03-07
EP1831174A1 (en) 2007-09-12
DE602005026703D1 (de) 2011-04-14
RU2396259C2 (ru) 2010-08-10
ATE500227T1 (de) 2011-03-15
JP2008525405A (ja) 2008-07-17
NO20073730L (no) 2007-09-10
TWI364415B (en) 2012-05-21
MY140868A (en) 2010-01-29
AU2005317868A1 (en) 2006-06-29
IL183657A (en) 2012-10-31
US7786115B2 (en) 2010-08-31
IL183657A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
AR055017A1 (es) Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos
AR046308A1 (es) Derivados amida
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
GB0517191D0 (en) Compounds
ATE517882T1 (de) Chinolinderivate
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
EP1430061A4 (en) INCLUSION COMPOUND CONTAINING CUCURBITURIL DERIVATIVES AS RECEPTOR MOLECULE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
PE20061397A1 (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos productos y metodos de preparacion
AR055303A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
MX2010003346A (es) Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
BRPI0408068A (pt) derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase
GB0507601D0 (en) Compounds
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
ATE473973T1 (de) Substituierte benzimidazole und deren verwendung zur induktion von apoptose
AR051771A1 (es) Acidos amino carboxilicos sustituidos
AR057975A1 (es) DERIVADOS DE QUINAZOLINAS, PROCESO DE OBTENCIoN Y COMPOSICIONES FARMACEUTICAS.
EP2202222A3 (en) Indene derivatives, their preparation and use as medicaments
CA3125731A1 (en) Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
AR067412A1 (es) Moduladores de propiedades farmaceuticas de productos terapeuticos
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
AR045694A1 (es) Derivados de quinazolina para el tratamiento de enfermedades proliferativas, composiciones farmaceuticas que los contienen y proceso para su preparacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal